This is a modest pipeline-expansion event for a clinical-stage biotech with no revenue. The collaboration validates OP-3136's combinability but carries no near-term financial catalyst. Watch for ASCO data on May 30, 2026, which could provide the first clinical proof-of-concept for OP-3136. Historical pattern of negative drift on OLMA neutral news suggests caution.
Price Chart
Executive Summary
Olema Oncology announced a clinical trial collaboration with Bayer to evaluate its KAT6 inhibitor OP-3136 in combination with darolutamide for metastatic castration-resistant prostate cancer (mCRPC). The Phase 1b/2 study will enroll approximately 36 patients and is expected to start in H2 2026. This is the first clinical collaboration for OP-3136, but the deal is non-financial (Bayer supplies drug, Olema runs the study) and the stock has historically declined on neutral news, with a 0% win rate at T+20 across prior reports.
Key Facts
- Olema and Bayer entered a clinical trial collaboration for OP-3136 (KAT6 inhibitor) + darolutamide in mCRPC.
- Phase 1b/2 study will enroll ~36 patients; initiation expected in H2 2026.
- Bayer supplies darolutamide; Olema leads the study and retains full global commercial rights to OP-3136.
- Initial Phase 1 monotherapy data for OP-3136 to be presented at ASCO on May 30, 2026.
- No upfront or milestone payments disclosed; deal is a drug-supply collaboration only.
- Historical OLMA reports show 0% win rate at T+20 (n=4 settled), with average T+20 return of -21.87%.
Financial Impact
No financial terms disclosed; Bayer provides darolutamide at no cost; Olema bears study costs.
Risk Factors
- Phase 1b/2 study may fail to show efficacy or safety in mCRPC.
- No financial terms disclosed — deal provides no capital infusion.
- Historical OLMA filings have consistently underperformed at T+20 (avg -21.87%).
- OP-3136 is early-stage (Phase 1); clinical and regulatory risks are high.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300930 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.23 (−21.14%) |
Aug 10, 2026 7w ago | Press Release | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.23 (−21.14%) |
Aug 9, 2026 7w ago | Institutional Cluster | $11.94 $10.99 | ▲ +8.00% | ▲ +7.08% | $8.23 (+31.11%) |
May 26, 2026 18w ago | 8-K | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.23 (−39.30%) |
May 26, 2026 18w ago | Press Release | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.23 (−39.30%) |
May 21, 2026 19w ago | 8-K | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.23 (−39.88%) |
May 21, 2026 19w ago | Press Release | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.23 (−39.88%) |
May 12, 2026 20w ago | 8-K | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.23 (−41.12%) |
May 12, 2026 20w ago | Press Release | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.23 (−41.12%) |
Apr 29, 2026 22w ago | DEFA14A | $14.41 $13.19 | ▼ −8.47% | ▼ −13.69% | $8.23 (−42.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access